INCY – incyte corporation (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day INCY SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/28/2025
07:00 am
incy
incyte corporation
BEAT
-5.7%
7/29/2025
07:00 am
incy
incyte corporation
BEAT
-0.7%
4/29/2025
07:00 am
incy
incyte corporation
MISS
-1.7%
2/10/2025
07:00 am
incy
incyte corporation
BEAT
-11.3%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
Top News Decliners
1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
INCY – incyte corporation (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
INCY
SPY
QQQ
SPX
INCY – incyte corporation (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
INCY SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/12
08:30 am
incy
Low
Incyte Announces Change to its Board of Directors
12/11
01:28 pm
incy
Low
Microsoft Corporation (MSFT) Presents at Barclays 23rd Annual Global Technology Conference Transcript [Seeking Alpha]
12/9
08:11 am
incy
Low
Incyte (NASDAQ:INCY) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
12/9
01:18 am
incy
Low
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? [Yahoo! Finance]
12/8
09:37 pm
incy
Low
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? [Yahoo! Finance]
12/8
04:30 pm
incy
Low
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
12/8
10:12 am
incy
Low
Incyte (NASDAQ:INCY) was given a new $92.00 price target on by analysts at Morgan Stanley.
12/8
08:12 am
incy
Medium
Incyte (NASDAQ:INCY) was given a new $121.00 price target on by analysts at Mizuho.
12/8
07:22 am
incy
Medium
Incyte (NASDAQ:INCY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
10/28/2025
07:00 am
incy
-5.7%
BEAT
7/29/2025
07:00 am
incy
-0.7%
BEAT
4/29/2025
07:00 am
incy
-1.7%
MISS
2/10/2025
07:00 am
incy
-11.3%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/9
08:11 am
Upgrades
Hold
Strong-Buy
Mizuho
Low
-1.5%
12/9
08:11 am
Upgrades
Hold
Strong-Buy
Mizuho
Low
-1.5%
12/8
12:38 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
-2.1%
12/8
12:38 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
-2.1%
12/8
09:49 am
Maintains
Overweight
Overweight
Wells Fargo
Low
-0.9%
12/8
09:49 am
Maintains
Overweight
Overweight
Wells Fargo
Low
-0.9%
12/8
08:45 am
Upgrades
Neutral
Outperform
Mizuho
Medium
-3.1%
12/8
08:45 am
Upgrades
Neutral
Outperform
Mizuho
Medium
-3.1%
12/8
07:22 am
Reiterates
Overweight
Overweight
Wells Fargo & Company
Medium
-7.2%
12/12
04:02 pm
incy
Low
Form 4 INCYTE CORP For: Dec 10 Filed by: Mayes Patrick A
12/12
11:35 am
incy
Low
Form 8-K INCYTE CORP For: Dec 10
12/11
04:13 pm
incy
Low
Form 144 INCYTE CORP Filed by: Mayes Patrick A
12/10
05:30 pm
incy
Low
Form 144 INCYTE CORP Filed by: Iyengar Vijay K
12/10
04:07 pm
incy
Low
Form 4 INCYTE CORP For: Dec 08 Filed by: Hoppenot Herve
12/10
04:04 pm
incy
Low
Form 144 INCYTE CORP Filed by: Mayes Patrick A
12/3
04:37 pm
incy
Low
Form 4 INCYTE CORP For: Dec 01 Filed by: Stein Steven H
12/3
04:36 pm
incy
Low
Form 4 INCYTE CORP For: Dec 01 Filed by: Morrissey Michael James
12/3
04:36 pm
incy
Low
Form 4 INCYTE CORP For: Dec 01 Filed by: Hoffman Richard A.
Show more
Top News Gainers
4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%
7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%
3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%
3/26 Incyte Names New Member to Its Board of Directors 5.9%
1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%
11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%
4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%
2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%
9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%
3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%
Top News Decliners
1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%
5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%
3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%
6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%
9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%
1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%
3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%
9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%
9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%
8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%